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Abstract 
Background: Candida parapsilosis (R)-carbonyl reductase (RCR) and (S)-carbonyl reductase (SCR) are involved in the 
stereoconversion of racemic (R,S)-1-phenyl-1,2-ethanediol (PED) to its (S)-isomer. RCR catalyzes (R)-PED to 2-hydroxy-
acetophenone (2-HAP), and SCR catalyzes 2-HAP to (S)-PED. However, the stereoconversion efficiency of racemic 
mixture to (S)-PED is not high because of an activity imbalance between RCR and SCR, with RCR performing at a lower 
rate than SCR. To realize the efficient preparation of racemic mixture to (S)-PED, an in situ expression of RCR and a two-
stage control strategy were introduced to rebalance the RCR- and SCR-mediated pathways.
Results: An in situ expression plasmid pCP was designed and RCR was successfully expressed in C. parapsilosis. With 
respect to wild-type, recombinant C. parapsilosis/pCP-RCR exhibited over four-fold higher activity for catalyzing race-
mic (R,S)-PED to 2-HAP, while maintained the activity for catalyzing 2-HAP to (S)-PED. The ratio of kcat/KM for SCR cata-
lyzing (R)-PED and RCR catalyzing 2-HAP was about 1.0, showing the good balance between the functions of SCR and 
RCR. Based on pH and temperature preferences of RCR and SCR, a two-stage control strategy was devised, where pH 
and temperature were initially set at 5.0 and 30 °C for RCR rapidly catalyzing racemic PED to 2-HAP, and then adjusted 
to 4.5 and 35 °C for SCR transforming 2-HAP to (S)-PED. Using these strategies, the recombinant C. parapsilosis/pCP-
RCR catalyzed racemic PED to its (S)-isomer with an optical purity of 98.8 % and a yield of 48.4 %. Most notably, the 
biotransformation duration was reduced from 48 to 13 h.
Conclusions: We established an in situ expression system for RCR in C. parapsilosis to rebalance the functions 
between RCR and SCR. Then we designed a two-stage control strategy based on pH and temperature preferences 
of RCR and SCR, better rebalancing RCR and SCR-mediated chiral biosynthesis pathways. This work demonstrates a 
method to improve chiral biosyntheses via in situ expression of rate-limiting enzyme and a multi-stage control strat-
egy to rebalance asymmetric pathways.
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Background
Optically active alcohols are versatile chiral build-
ing blocks for organic synthesis in a variety of different 
industries. Considerable research efforts have recently 
focused on the preparation of chiral compounds using 
enzyme-catalyzed bioprocesses [1, 2]. Stereospecific 
carbonyl reductases are good candidates to catalyze 
prochiral ketones to the corresponding enantiopure alco-
hols [3–5]. For example, Candida parapsilosis CCTCC 
M203011 contains (R)- and (S)-carbonyl reductases (RCR 
and SCR), which catalyze the biotransformation of the 
valuable, optically active (S)-1-phenyl-1,2-ethanediol 
(PED) (Fig. 1), which can be used for synthesis of an anti-
depressant drug, fluoxetine, which extends the effects of 
5-hydroxy tryptamine through selective inhibition for 
the extraction of 5-hydroxy tryptamine in central nerv-
ous system [6, 7]. The enzymatic biosynthesis of (S)-PED 
involves two sequential redox reactions: (i) RCR cata-
lyzes reversible conversion of 2-hydroxyacetophenone 
(2-HAP) to (R)-PED; and (ii) SCR catalyzes reduction of 
the intermediate 2-HAP to (S)-PED. The asymmetric flux 
of this process is controlled by the activity of the RCR 
and SCR enzymes, with the initial RCR-catalyzed reac-
tion being the rate-limiting step. It was reported that 
wild-type (WT) C. parapsilosis and recombinant Escheri-
chia coli containing RCR and SCR biotransform (R)-PED 
to the corresponding (S)-isomer with low yields, most 
likely because of the unbalanced efficiency of turnover of 
the enzymes [8, 9].
Many carbonyl reductases have been engineered in dif-
ferent host cells to improve their catalytic activity and/or 
protein production [10, 11]. However, some recombinant 
carbonyl reductases have been reported to exhibit low or 
no enzymatic activity, which could be caused by incorrect 
protein folding or lack of post-translational modifications 
[11, 12]. For example, the specific activities of carbonyl 
reductase and pyranose dehydrogenase expressed in 
yeast were much higher than those in E. coli [13, 14].
In our previous study, we successfully expressed the 
RCR and SCR enzymes of C. parapsilosis in different host 
cells, including E. coli [15], Saccharomyces cerevisiae [16] 
and Pichia pastoris [13, 17]. Unfortunately, these recom-
binant enzymes produced the desired chiral PED with 
low yields over a long reaction time of 48 h [13, 15–17]. 
The recently developed in  situ expression technique 
offers a new approach for increasing protein activity 
and production since the natural host supplies the bet-
ter environment for protein-folding than heterogenous 
host. Yang et al. efficiently produced 2,3-butanediol using 
an in  situ expression system containing glyceraldehyde-
3-phosphate dehydrogenase and 2,3-butanediol dehy-
drogenase in Bacillus amyloliquefaciens [18]. Piskin et al. 
proved that in  situ expression of IL-23 by keratinocytes 
in healthy skin and psoriasis lesions enhanced expres-
sion in psoriatic skin [19]. Kasai et al. reported increased 
expression of type I 17β-hydroxysteroid dehydrogenase 
enhances in  situ production of estradiol in uterine leio-
myoma [20]. The in  situ expression of RCR in C. par-
apsilosis may provide the appropriate environment for 
correct protein-folding and improve its catalytic activ-
ity. C. parapsilosis is the major fungal pathogen and is of 
significant medical and biotechnological importance, so 
the successful genetic manipulation of this fungus will 
ultimately lead to the identification of valuable new bio-
technological processes [21]. The genetic manipulation of 
Candida species has been challenging because they lack 
natural plasmids [22, 23]. The reported gene disruption 
method in Candida strains by Reuß et  al. [24–26] and 
the molecular genetics of Candida albicans by De Backer 
et al. [27] might supply convenient technical information 
for in situ protein expression in Candida species.
In this work, to improve the biotransformation effi-
ciency of racemic (R,S)-PED to its (S)-isomer by C. par-
apsilosis through improving RCR activity to rebalance the 
functions of RCR and SCR, we designed a special vector 
pCP for in situ expression of RCR in C. parapsilosis. The 
catalytic efficiency of RCR was significantly enhanced, 
better rebalancing the RCR and SCR functions. Based 
on pH and temperature preferences of RCR and SCR, 
we proposed a two-stage control strategy to rebalance 
RCR and SCR-mediated asymmetric biosynthetic path-
way. The in  situ expression system C. parapsilosis/pCP-
RCR catalyzed racemic PED to (S)-PED with high optical 
purity of 98.8 % and a high yield of 48.4 %. More impor-
tantly, the biotransformation process was decreased from 
Fig. 1 The stereoinversion of, (R,S)-PED to its (S)-isomer by RCR and 
SCR from C. parapsilosis. An NAD+-dependent RCR catalyzes the 
reversible reaction between (R)-PED and 2-HAP. An NADPH-linked 
SCR transforms the intermediate 2-HAP to (S)-PED. The oxidation 
of (R)-PED to 2-HAP is rate-limiting step during the stereoinversion 
of racemic (R,S)-PED to its (S)-isomer. The desired product (S)-PED is 
underlined. PED, 1-phenyl-1,2-ethanediol; RCR, (R)-carbonyl reductase; 
SCR, (S)-carbonyl reductase
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48 to 13  h. This work provides a method for improving 
chiral biosynthesis efficiency through the in situ expres-
sion of a rate-limiting enzyme and a two-stage pH and 
temperature control strategy to rebalance multi-enzyme 
mediated asymmetric pathways.
Results
Design of in situ expression system of RCR in C. parapsilosis
The in situ expression plasmid pCP-rcr containing 6× His-
tagged RCR was constructed using standard techniques 
described in the “Methods” section. Briefly, a 5′-terminal 
548-bp fragment of a mal2 ortholog was used to drive rcr 
expression, and a 3′-terminal 388-bp fragment of an act1 
ortholog to terminate rcr expression. An act1 promoter 
(1141 bp) and an ura3 terminator (508 bp) were used to 
control sat1 expression, which conferred nourseothricin 
resistance in C. parapsilosis [24, 28]. Since seven DNA 
fragments (ura3p, mal2p, rcr, act1t, act1p, sat1 and ura3t) 
were cloned into pUC57 simultaneously to construct the 
recombinant pCP-rcr (Fig.  2), some of their restriction 
enzyme recognition sites were mutated, and the enzyme 
digestion and overlap-extension PCR techniques were 
both used. The length of expression cassette ura3p-mal2p-
rcr-act1t-act1p-salt-ura3t was about 4.5  kb. Recombi-
nant plasmid pCP-rcr was transformed into E. coli DH5α 
competent cells to construct E. coli DH5α/pCP-rcr. Sub-
sequent nucleotide sequencing confirmed that the expres-
sion cassette ura3p-mal2p-rcr-act1t-act1p-salt-ura3t had 
been correctly cloned into pCP-rcr plasmid.
In situ expression of RCR rebalanced the RCR and SCR 
functions
EcoRI linearized pCP-rcr plasmid was transformed into 
C. parapsilosis by electroporation. C. parapsilosis/pCR-
rcr transformants were selected using nourseothricin as 
a positive selection marker and a uracil auxotroph as a 
negative selection marker. Colony PCR was carried out 
using RCR_1 and RCR_2 as primers, and subsequent 
nucleotide sequencing confirmed that the rcr gene was 
integrated into the C. parapsilosis genome. SDS-PAGE 
analysis showed that a predominant band corresponding 
to the expected size of the 6× His-tagged RCR enzyme 
(37 kDa) was observed in cell-free extracts of C. parap-
silosis/pCR-rcr. The expression of recombinant RCR 
reached the highest level at 30 h. The expression of RCR 
was obviously low in WT C. parapsilosis with a molecu-
lar size of 36 kDa (Fig. 3a).
RCR has two functions including oxidation of (R)-PED 
to 2-HAP and reduction 2-HAP to (R)-PED. Recombi-
nant C. parapsilosis/pCP-rcr showed a specific activ-
ity of 0.74  U/mg for (R)-PED oxidation, and 0.15  U/mg 
for 2-HAP reduction in the cell-free extracts, while WT 
C. parapsilosis presented 0.04 U/mg for (R)-PED oxida-
tion, and 0.16  U/mg for 2-HAP reduction (Table  1). The 
recombinant C. parapsilosis/pCP-rcr showed 4–5 folds 
higher oxidative and reductive activity than WT. But the 
two strains presented the same activity for reduction of 
2-HAP to (S)-PED in the cell-free extracts. The recombi-
nant C. parapsilosis/pCP-rcr biotransformed racemic PED 
to its (S)-isomer with an optical purity of 95.6 % and a yield 
of 43.5 % in 30 h. Compared to WT, recombinant C. par-
apsilosis/pCP-rcr improved the optical purity and yield of 
(S)-PED 3.4 and 32.6 %, respectively. Notably, the biotrans-
formation process was shortened from 48 to 30 h (Table 1).
RCR and SCR mediated biotransformation of racemic 
PED to (S)-PED contains two steps: RCR catalyzes (R)-
PED to 2-HAP; SCR catalyzes 2-HAP to (S)-PED. The 
kinetic parameters of RCR catalyzing (R)-PED oxida-
tion and SCR catalyzing 2-HAP reduction were assessed 
in WT and recombinant C. parapsilosis/pCP-rcr. The 
recombinant C. parapsilosis/pCP-rcr showed about two-
fold higher kcat value than WT, but maintained Km value 
towards (R)-PED oxidation. WT and recombinant C. 
parapsilosis/pCP-rcr showed almost the same Km and kcat 
Fig. 2 Construction of an expression cassette for RCR in C. parapsilosis. ura3p (upstream sequence of ura3 gene) and ura3t (downstream sequence 
of ura3 gene) fragments were amplified using primers URA3p_1/URA3p_2 and URA3t_1/URA3t_2, and used as homologous regions for insertion 
into the genome. mal2p (upstream sequence of mal2 gene) and act1p (upstream sequence of act1 gene) fragments were amplified using primers 
MAL2p_1/MAL2p_2 and ACT1p_1/ACT1p_2, and used as the promoters for expression of the rcr and sat1 genes, respectively. act1t (downstream 
sequence of act1 gene) and ura3t (downstream sequence of ura3 gene) fragments were amplified using primers ACT1t_1/ACT1t_2 and URA3t_1/
URA3t_2, and used as the terminators for the rcr and sat1 genes, respectively. Restriction sites are unique. E EcoRI, B BglII, S SacI, K KpnI, P PstI, N NotI, 
BH BamHI, H Hind III
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values towards 2-HAP reduction (Table  2). The relative 
kcat/Km of RCR and SCR was 2.08 in WT C. parapsilosis, 
while it was 1.14 in C. parapsilosis/pCP-rcr (Table 2), sug-
gesting the better rebalance of RCR and SCR functions.
Purification of RCR and SCR and their temperature and pH 
dependence
Recombinant RCR with a C-terminal His6-tag was puri-
fied using the standard technique in the “Methods” 
section. The proteins were purified to apparent homoge-
neity by SDS-PAGE (Fig. 3b). SCR was purified from the 
recombinant C. parapsilosis/pCP-rcr according to meth-
ods described by Zhang et al. [17].
The pH and temperature dependences of purified RCR 
were determined. The recombinant RCR showed its opti-
mal pH 5.0 and 30  °C for catalyzing (R)-PED to 2-HAP, 
and pH 6.5 and 35 °C for catalyzing 2-HAP to (R)-PED at 
pH 6.5 and 35 °C (Additional file 1: Figures S1, S2). When 
Fig. 3 a SDS-PAGE analysis of RCR expression at different time points in recombinant C. parapsilosis/pCP-RCR. The cell-free extracts of C. parapsilosis/
pCP-RCR collected at different time points were separated on 15 % polyacrylamide gels. Lane M, protein molecular standards. b SDS-PAGE analysis 
of purified RCR. ReQ the fraction purified by Resource Q chromatography; S200 the fraction purified by Superdex-200 chromatography; SCR purified 
SCR from C. parapsilosis/pCP-RCR; Lane M, protein molecular standards
Table 1 The specific activities of  RCR and  SCR in  the cell-free extracts of  recombinant C. parapsilosis/pCP-rcr and  wild-
type C. parapsilosis
a The reductive activities of RCR catalyzing (R)-PED to 2-HAP were determined using NADH as cofactor. The oxidative activities of RCR catalyzing 2-HAP to (R)-PED 
were determined using NAD+ as cofactor











Yield (%) Duration 
(h)
C. parapsilosis 0.04 ± 0.00 0.16 ± 0.08 0.39 ± 0.03 92.5 ± 1.7 32.8 ± 0.8 48
C. parapsilosis/pCP-rcr 0.15 ± 0.01 0.74 ± 0.07 0.40 ± 0.04 95.6 ± 2.1 43.5 ± 1.0 30
Table 2 Kinetic parameters for oxidation of (R)-PED to 2-HAP by RCR and reduction of 2-HAP to (S)-PED by SCR in recom-
binant C. parapsilosis/pCP-rcr and wild-type C. parapsilosis
All reactions involved in the calculation of kinetics constants were assayed with 100 mM acetate buffer (pH 6.5) at 35 °C. All experiments were repeated three to five 
times
a Relative kcat/Km between oxidation of (R)-PED to 2-HAP by RCR and reduction of 2-HAP to (S)-PED by SCR
Strains Oxidation of (R)-PED to 2-HAP by RCR Reduction of 2-HAP to (S)-PED by SCR Relativea kcat/Km
Km (mM) kcat (S
−1) kcat/Km (S
−1 mM−1) Km (mM) kcat (S
−1) kcat/Km (S
−1 mM−1)
C. parasilosis 6.53 ± 0.20 1.88 ± 0.14 0.29 4.36 ± 0.13 2.58 ± 0.05 0.59 2.03
C. parapsilosis/pCP-rcr 6.31 ± 0.09 3.19 ± 0.22 0.51 4.39 ± 0.10 2.53 ± 0.02 0.58 1.14
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RCR was kept at temperatures below 40 °C for 1 h or pH 
4.5–6.5 for 48 h, it retained >70 % of its maximum oxida-
tive and reductive activity (Additional file 1: Figures S1, 
S2).
The enzyme SCR was purified from recombinant C. 
parapsilosis/pCP-rcr. It showed its optimal pH 4.5 and 
35  °C for catalyzing 2-HAP to (S)-PED at pH 4.5 and 
35 °C. When SCR was incubated at pH 4.0–7.0 for 48 h 
or 40 °C for 1 h, about 80 % of its maximum activity was 
retained (Additional file 1: Figures S3, S4).
The biotransformation of (R)-PED to (S)-isomer under the 
optimum conditions of RCR and SCR
Under the optimum conditions for RCR catalyzing (R)-
PED to 2-HAP (i.e., pH 5.0 and 30  °C), the recombi-
nant C. parapsilosis/pCP-rcr cells converted racemic 
(R,S)-PED to (S)-PED and the reaction reached a good 
balance in 24  h. At that time, the consumption rate of 
(R)-PED and the formation rate of (S)-isomer was almost 
the same, and 2-HAP was maintained at a stable level 
(Fig. 4a). (S)-PED was produced with an optical purity of 
93.7 % and a yield of 46.5 %.
Under the optimum conditions for RCR catalyzing 
2-HAP to (R)-PED (i.e., pH 6.5 and 35  °C), There are 
three distinct stages during the biotransformation of 
racemic (R,S)-PED to (S)-PED by recombinant C. par-
apsilosis/pCP-rcr. In the initial stage (0–12  h), (R)-PED 
was transformed to 2-HAP. But the intermediate 2-HAP 
could not be rapidly transformed to (S)-PED, resulted in 
2-HAP accumulation to the highest level (1.5 g/L) at 12 h 
(Fig.  4b). At that time, the ratio of the concentration of 
(R)-PED to (S)-PED was about 2:1. In the middle stage 
(12–16  h), the intermediate 2-HAP was almost com-
pletely consumed and transformed to (R)-PED. In the 
final stage (16–55  h), (R)-PED concentration gradually 
decreased and was transformed to 2-HAP by RCR; and 
2-HAP was then rapidly converted to (S)-PED by SCR 
until the (R)-PED was almost completely consumed 
(Fig.  4b). Finally, recombinant C. parapsilosis/pCP-rcr 
catalyzed racemic mixture to its (S)-PED with an optical 
purity of 94.7 % and a yield of 48.1 % in 55 h.
Significantly improved biotransformation efficiency 
of (S)-PED using a two-stage control strategy
To improve stereoinversion efficiency of racemic (R,S)-
PED to (S)-PED and shorten biotransformation dura-
tion, a two-stage control strategy was devised based on 
the optimal conditions of two sequential reactions: RCR 
catalyzing (R)-PED to 2-HAP and SCR catalyzing 2-HAP 
to (R)-PED. In an asymmetric 10-mL reactor, the pH and 
temperature were initially set at 5.0 and 30  °C for RCR 
rapidly catalyzing (R)-PED to 2-HAP (Fig. 5). The initial 
level of 10 g/L racemic (R,S)-PED quickly decreased and 
most of substrate was consumed in 8 h by recombinant 
C. parapsilosis/pCP-rcr. At that time, the intermediate 
2-HAP reached its highest level (1.8 g/L). Then the bio-
transformation conditions were adjusted to 35  °C and 
pH 4.5 for SCR quickly converting 2-HAP to (S)-PED. 
The residual substrate racemic (R,S)-PED and the inter-
mediate 2-HAP were both consumed and transformed to 
(S)-PED from 8 h to 13 h (Fig. 5). During the final stages 
(from 12 to 13  h), there was few residual intermediate 
Fig. 4 The biotransformation course of racemic (R,S)-PED to its (S)-isomer by recombinant C. parapsilosis/pCP-RCR cells. a Biotransformation carried 
out using 2-HAP as substrate; b biotransformation carried out using racemic (R,S)-PED as substrate
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2-HAP. Finally, recombinant C. parapsilosis/pCP-rcr cat-
alyzed racemic mixture to (S)-PED with an optical purity 
of 98.8 % and a yield of 48.4 % in 13 h.
Discussion
Candida parapsilosis transformes racemic PED to its (S)-
isomer including two steps: RCR catalyzes the oxidation 
of (R)-PED to 2-HAP, and SCR catalyzes the reduction of 
2-HAP to (S)-PED. However, C. parapsilosis and recom-
binant E. coli-RCR-SCR catalyzed the biotransforma-
tion of (S)-PED with a yield of 75–83 %, and the process 
required a long time (48 h) [8, 9]. By analysis of RCR and 
SCR functions, we found that SCR showed much higher 
overall activity than RCR, which may be due to its exhib-
iting more correct protein folding and higher protein 
expression in C. parapsilosis and other host cells [8, 29]. 
Moreover, a cluster of four SCR isozymes was recently 
found in C. parapsilosis [30], which enlarged the activity 
gap between RCR and SCR.
In this work, we designed a special expression plasmid 
pCP by cloning the expression components into pUC57, 
and introduced an in situ expression system of RCR into 
C. parapsilosis to strengthen RCR function. To improve 
screening probability of the positive C. parapsilosis/pCP-
rcr clones, the RCR expression cassette was designed 
using nourseothricin as a positive selection marker and 
a uracil auxotroph as a negative selection marker. The 
minimal inhibitory concentration of nourseothricin was 
60  μg/ml in C. parapsilosis. Reuss et  al. used the drug 
nourseothricin as a dominant selectable marker for gene 
disruption in C. albicans [31]. Shen et al. used the nour-
seothricin adapted to suit C. albicans in a Ca-NAT1–FLP 
cassette [32]. However, the concentration of nourseothri-
cin used in C. albicans was different from that of in C. 
parapsilosis which may be due to the different resistance 
levels of two Candida strains. Using this screening tech-
nique, we selected the clones with the highest activities 
from about 120 positive C. parapsilosis clones.
The constitutive expression of 6× his tagged RCR 
strengthened its function in C. parapsilosis. The recom-
binant C. parapsilosis/pCP-rcr showed over fourfold 
higher activities for catalyzing (R)-PED to 2-HAP than 
WT, which may be due to the integration of several cop-
ies of the RCR gene into the C. parapsilosis genome [21, 
33]. The introduction of in  situ expression of RCR had 
no effect on the cell-growth and SCR activity. The in situ 
expression of RCR did not change Km value towards (R)-
PED oxidation, and Km and kcat values towards 2-HAP 
reduction, but increased kcat value towards (R)-PED oxi-
dation about two times. The relative kcat/Km of SCR cata-
lyzing 2-HAP and RCR catalyzing (R)-PED was about 2 
in WT C. parapsilosis, indicating the imbalance between 
RCR and SCR functions, with SCR performing at a higher 
rate than RCR. The relative kcat/Km value was about 1 
Fig. 5 Optimized biotransformation of racemic (R,S)-PED to its (S)-isomer through a two-stage control strategy. The temperature and pH were set at 
30 °C and 5.0 in 8 h, and then converted at 35 °C and 4.5 from 9 to 13 h. The recombinant C. parapsilosis/pCP-RCR cells catalyzed racemic (R,S)-PED 
to its (S)-isomer with a high optical purity (98.8 %) and a yield of 48.4 % within 13 h without addition of cofactors
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in C. parapsilosis/pCP-rcr, suggesting good rebalance 
between RCR and SCR functions. The obviously higher 
kcat/Km value of RCR in C. parapsilosis/pCP-rcr than that 
of in WT may be due to the 6× histine tag at N-terminal 
of RCR in C. parapsilosis/pCP-rcr. Yeon et  al. thought 
that the catalytic activity of 3-hydroxybutyrate dehydro-
genase was not severely affected by the N-terminal His-
tag due to the location of the N-terminus far from the 
active site of the enzyme [34]. Dickson et al. reported that 
the N-terminus His-tag did result in a differential effect 
on protein kinase activity, further potentiating the ele-
vated protein kinase activity of both the helical domain 
and catalytic domain oncogenic mutants with relation to 
p110 phosphorylation [35]. The introduction of in  situ 
expression of RCR better rebalanced RCR and SCR func-
tions, resulting in obviously improved optical purity and 
yield of (S)-PED during the biotransformation of racemic 
PED to its (S)-isomer. Compared to WT, the recombi-
nant C. parapsilosis/pCP-rcr reduced the biotransforma-
tion duration from 48 to 36 h.
To further improve the stereoconversion efficiency 
of racemic (R,S)-PED to its (S)-isomer by recombinant 
C. parapsilosis/pCP-rcr, the biotransformation process 
should be optimized. Since RCR not only catalyzes oxi-
dation of (R)-PED to 2-HAP, but also catalyzes reduction 
of 2-HAP to (R)-PED. The latter function is unfavorable 
for the biotransformation of racemic PED to (S)-PED. 
By analysis of the whole biotransformation process, 
we found much time was wasted in the reversible reac-
tion between 2-HAP and (R)-PED. Basing on pH and 
temperature preferences of RCR catalyzing (R)-PED to 
2-HAP and SCR catalyzing 2-HAP to (S)-PED, we envis-
aged a two-stage control strategy to optimize the asym-
metric biotransformation process. The biotransformation 
was first carried out under the optimal conditions for 
RCR rapidly catalyzing (R)-PED to 2-HAP, then under 
the optimal conditions for SCR converting 2-HAP to 
(S)-PED. Using these strategies, the recombinant C. par-
apsilosis/pCP-rcr strains efficiently converted racemic 
(R,S)-PED to the (S)-isomer with good performance: an 
optical purity of 98.8 % and a yield of 48.4 %. Since race-
mic (R,S)-PED contains 50  % (S)-PED, the final yield of 
(S)-PED by the recombinant C. parapsilosis/pCP-rcr is 
98.4 %. Zhang et al. reported one-step biotransformation 
of (R)-PED to (S)-isomer by an enzyme-coupled system E. 
coli/pET-RCR-SCR. The system produced (S)-PED with 
an optical purity of 91.3 % and a yield of 75.9 % in 48 h 
[8]. Nie et al. enhanced the biotransformation efficiency 
of (R,S)-PED to its (S)-isomer with an optical purity of 
98.2 % and a yield of 82.9 % in 48 h using agitation speed 
control strategy during cell cultivation of C. parapsilo-
sis CCTCC 203011 [9]. Compared with the E. coli/pET-
RCR-SCR and WT C. parapsilosis, the recombinant C. 
parapsilosis/pCP-rcr increased the yield of (S)-PED about 
18.7–29.3  %. More importantly, the biotransformation 
time was reduced about four-fold: from 48 to 13 h [8, 9].
Conclusions
There is much imbalance between the activities of RCR 
and SCR, resulting in a low biotransformation efficiency 
of racemic (R,S)-PED to its (S)-isomer by C. parapsilosis. 
In this work, we designed an in situ expression plasmid, 
pCP, and expressed RCR in C. parapsilosis to narrow the 
function gap between RCR and SCR. Then we developed 
a two-stage control strategy based on pH and tempera-
ture preferences of RCR and SCR. The in situ expression 
system biotransformed racemic (R,S)-PED to its (S)-iso-
mer with good performance: an optical purity of 98.8 % 
and a yield of 48.4 %. Most notably, the biotransformation 
duration was reduced about four times: from 48 to 13 h 
with respect to the WT. This work provides a method for 
improving chiral biosynthesis efficiency through in  situ 
expression of a rate-limiting enzyme and a two-stage 
control strategy to rebalance asymmetric pathways. Fur-
ther research will be carried out using the safer micro-




NADPH and 2-HAP were obtained from Sigma-
Aldrich Chemical Co., Inc. (St. Louis, USA). Restriction 
enzymes, nourseothricin, uracil and 5-fluoroorotic acid 
were obtained from Takara Bio. Co. (Kyoto, Japan). All 
other chemicals were of the high grade commercially 
obtainable.
Organisms and culture conditions
Candida parapsilosis CCTCC M203011 was obtained 
from the American Type Culture Collection. It was cul-
tured in yeast extract peptone-dextrose medium (1  % 
yeast extract, 2 % glucose, 2 % peptone) at 30 °C. E. coli 
DH5α was grown in lysogeny broth medium (0.5 % yeast 
extract, 1 % NaCl, 1 % peptone) at 37 °C. When nesseary, 
60 μg/ml nourseothricin and 20 μg/ml uracil was added. 
Recombinant C. parapsilosis were cultured in medium 
containing 0.5  % yeast extract, 4  % maltose, 1.3  % 
(NH4)2HPO4, 0.7  % KH2PO4, 0.01  % NaCl, and 0.08  % 
MgSO4·7H2O with the addition of 60 μg/ml nourseothri-
cin and 20 μg/ml uracil.
Construction of the in situ expression plasmid pCP-rcr
Plasmids, strains and primers used in this work are listed 
in Additional file 1: Table S1 in the supplemental mate-
rial. The SAT1-flipper method and ura3-negative method 
were used to construct the RCR in  situ expression 
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plasmid for C. parapsilosis. The promoter act1A gene 
(GenBank ID: AJ389062.1) was amplified from the 
C. parapsilosis genome using primers ACT1p_1 and 
ACT1p_2, and was cloned into the corresponding NotI/
HindIII sites of pMD19-T (Takara Co., Dalian, China), 
resulting in the recombinant plasmid T-act1p. The 
sat1 gene (KF318043.1) (of 525-bp) was amplified with 
primers SAT1_1 and SAT1_2 (NotI/BamHI). The ura3 
(3636649) downstream fragment (508  bp) was cloned 
using primers URA3t_1 and URA3t_2 (BamHI/HindIII). 
The sat1-ura3t fragment was generated using a modi-
fied overlap-extension technique [36] with the primers 
SAT1_1 and URA3t_2. The NotI/HindIII fragment of 
sat1-ura3t was inserted into plasmid T-act1p to gen-
erate the plasmid T-act1p-sat1-ura3t. The upstream 
sequence of ura3 (285-bp) was amplified with primers 
URA3p_1 and URA3p_2 (EcoRI/BglII), and the mal2 pro-
moter (3638946) (548  bp) was amplified using primers 
MAL2p_1 and MAL2p_2 (BglII/SacI). The ura3p-mal2p 
fragment was generated using primers URA3p_1 and 
MAL2p_2. The EcoRI/SacI fragment of ura3p-mal2p was 
inserted into pUC57 to generate plasmid pUC57-ura3p-
mal2p. The rcr gene (GenBank ID: DQ295067) with a 6× 
His-tag at the C-terminus was amplified from the C. par-
apsilosis genome with primers RCR_1 and RCR_2 (con-
taining recognition sites for SacI and KpnI), and cloned 
into pUC57-ura3p-mal2p to generate pUC57-ura3p-
mal2p-rcr. The act1 downstream sequence (388-bp) was 
amplified with primers ACT1t_1 and ACT1t_2 (con-
taining recognition sites for KpnI and PstI), and cloned 
into pUC57-ura3p-mal2p-rcr, generating pUC57-ura3p-
mal2p-rcr-act1t. The plasmid T-act1p-sat1-ura3t was 
digested with PstI and HindIII and then inserted into 
pUC57-ura3p-mal2p-rcr-act1t, generating the recombi-
nant plasmid pUC57-ura3p-mal2p-rcr-act1t-act1p-salt-
ura3t, named pCP-rcr. All the recombinant plasmids 
were verified by DNA sequencing.
Electrotransformation of C. parapsilosis
Candida parapsilosis cells were cultured overnight until 
the OD600 value reached 2.0, and were then inoculated 
into 50  ml yeast extract peptone-dextrose medium at 
30 °C. When the OD600 value of the culture reached 1.0–
2.0, the culture was resuspended in 50 ml of Tris–EDTA 
buffer (pH 7.5) containing 10 mM dithiothreitol, and was 
then kept on ice for 30 min. After the cells were washed 
four times using 10 ml of 1 M ice-cold sorbitol, the com-
petent cells were resuspended in 80 μl 1 M sorbitol. The 
vector pCP-rcr was linearized with EcoRI and then trans-
formed into C. parapsilosis with a MicroPulser electropo-
rator (Bio-Rad, USA) at 2000 V in a 1-mm cuvette. After 
electroporation, 1 ml of ice-cold 1 M sorbitol was imme-
diately added. The cells were incubated at 30  °C for 2  h 
and collected at 4000×g for 10 min. After resuspension in 
100 μl sorbitol (1 M), the cultures were plated onto mini-
mal dextrose plates containing 60  μg/ml nourseothricin 
and 20 μg/ml uracil. The C. parapsilosis/pCR-rcr transfor-
mants were obtained after incubation for 48 h.
Cell-free extract preparation
Recombinant C. parapsilosis cells were grown for 48  h 
in medium containing 0.5  % yeast extract, 4  % maltose, 
1.3  % (NH4)2HPO4, 0.7  % KH2PO4, 0.01  % NaCl, and 
0.08  % MgSO4·7H2O. When necessary, 60  μg/ml nour-
seothricin was added into the medium. The cells were 
harvested by centrifugation and washed twice with 0.8 % 
NaCl solution, and then suspended in 0.1  M potas-
sium phosphate buffer (pH 6.5). WT C. parapsilosis and 
recombinant C. parapsilosis/pCR-rcr cells were har-
vested and broken using an APV 2000 homogenizer (SPX 
Co. Unna, Germany). The homogenate was centrifuged 
at 48,000×g for 40 min. The supernatant of WT C. par-
apsilosis and recombinant C. parapsilosis/pCR-rcr was 
used for further enzyme assay and protein purification.
Enzyme assay
The mixture for assaying reductive activity of RCR con-
tained 0.1  M potassium phosphate buffer (pH 6.5), 
0.5 mM NADH/NADPH, 5 mM 2-HAP, and an appropri-
ate amount of RCR or the cell-free extracts of WT and 
recombinant C. parapsilosis/pCR-rcr in a total volume 
of 100  µl. The mixture for assaying oxidative activity of 
RCR comprised 0.1  M potassium phosphate buffer (pH 
6.5), 0.5 mM NAD+, 5 mM (R)-PED, and an appropriate 
amount of RCR or cell-free extracts of WT and C. parap-
silosis/pCR-rcr in a total volume of 100 µl. The decrease/
increase in the concentration of NAD(P)+ or NAD(P)
H was recorded spectrophotometrically at 340  nm. The 
reduction activity of SCR was measured as described 
by Zhang et  al. [13]. One unit of enzyme activity was 
defined as the amount of enzyme catalyzing the oxida-
tion/reduction of 1  µmol NAD(P)H/NAD(P)+ per min-
ute in the assay conditions. The protein concentration 
was determined using Bradford reagent (Bio-Rad) with 
bovine serum albumin as the standard [37]. Reported 
values represent the average of at least three independent 
measurements.
Temperature and pH dependence of enzymes
The temperature dependence of enzyme activity was 
determined from 10 to 60 °C. The pH dependence of the 
reductive activity was determined between pH 4.0 and 
9.0 using 100  mM citrate buffer (pH 3.0–4.5), 100  mM 
sodium acetate buffer (pH 4.0–6.0), 100  mM potassium 
phosphate buffer (pH 6.0–7.0) or 100  mM Tris–HCl 
buffer (pH 7.0–9.0) at 35  °C. The enzyme activity was 
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otherwise measured with the standard assay method 
described above.
Stability of enzymes
Thermostability was determined by incubation of the 
purified RCR and SCR (0.2  mg/ml) in 100  mM NaAC-
HAC buffer, pH 6.0, at temperatures between 10 and 
60  °C. The pH stability of enzymes was determined by 
incubating purified enzyme at pH 3.0–9.0 and 35  °C. 
After exposure of enzyme to the indicated conditions for 
1 h, samples were taken to assay for residual activity.
Protein purification
Recombinant RCR were expressed in C. parapsilosis 
with a His6-tag. Cell-free fractions were applied to Ni2+-
Sepharose affinity chromatography columns (HisTrap 
Kit, GE Healthcare, Uppsala, Sweden) using an ÄKTA 
Protein Purifier system. The pooled fractions were then 
loaded onto a Resource Q column (1  ×  1  cm) equili-
brated with 20 mM Tris–HCl (pH 8.0). Finally, the frac-
tions were applied to a Superdex 200 column (HiLoad 
26/60, preparation grade) for chromatography in a buffer 
containing 20 mM Tris–HCl (pH 8.0) and 150 mM NaCl. 
The homogeneity of purified enzymes was judged by 
Coomassie Brilliant Blue staining of SDS-PAGE.
Determination of kinetic parameters
To determine the kinetic parameters, various concen-
trations of substrate 2-HAP or (R)-PED (0.5–20  mM), 
enzyme (10–200  μM), and cofactors NAD+ or NADPH 
(0.5–5.0  mM) in 0.1  M NaAC-HAC buffer (pH 6.5) at 
35  °C were used. The data were fitted to the Michae-
lis–Menten equation by using a nonlinear least-square 
iterative method using KaleidaGraph (Synergy Software, 
Reading, PA). Three sets of kinetic parameters were 
obtained from three independent experiments and then 
simply averaged to yield the final estimates. The final esti-
mates are shown with the standard errors for the three 
sets.
Biotransformation and analytical methods
The biotransformation was carried out as previously 
described [9] with minor modifications. The reaction 
mixture in 1  ml contained 0.1  M potassium phosphate 
buffer (pH 6.5), 10 mg racemic (R,S)-PED, and 0.1 g wet 
cells at 35 °C, or 0.1 M NaAC-HAC buffer (pH 5.0), 10 mg 
racemic (R,S)-PED, and 0.1  g wet cells at 30  °C. Reac-
tions were carried out for 48 h with shaking at 220 rpm. 
Through a two-stage pH and temperature control strat-
egy, the reaction mixture in 10 ml contained 0.1 M potas-
sium phosphate buffer, 10  mg racemic (R,S)-PED, and 
1.0 g wet cells. The biotransformation was carried out at 
pH 5.0 and 30  °C for 8  h, then at pH 4.5 and 35  °C for 
5 h. The products were extracted with ethyl acetate and 
the organic layer was analyzed by high-performance liq-
uid chromatography on a Chiralcel OB-H column (Daicel 
Chemical Ind. Ltd., Japan). The conditions for the HPLC 
analyses—mobile phase, hexane:isopropanol 9:1; flow 
rate: 0.4  ml/min, operating column temperature: 38  °C; 
and UV detector. The optical purity and yield of products 
were calculated using the following equations [9]:
 
 (R)-PED, (S)-PED and 2-HAP are measured in grams.
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